Seagate Ships 30TB Drives to Meet Global Surge in Data Center AI Storage Demand
'Today, approximately 90% of the world's data is stored in just 10 countries. However, data gravity is increasingly pulling networks to the edge as nearly 150 countries adopt data sovereignty requirements, and AI workloads continue to expand. Datacenters—on-prem, private, and sovereign—are leveraging AI to unlock the value of their proprietary data,' said Melyssa Banda, SVP of Edge Storage and Services, Seagate. 'Our 30TB drives are designed to support these rapidly growing trends, delivering the capacity, efficiency, and resilience needed to power the AI workloads.'
Industry leaders are aligning around the fundamental data management and infrastructure shifts:
"Hyperscalers and enterprise data centers are in the early stages of an all-out arms race to develop AI infrastructure resulting in rapidly increasing capex spending on performance-oriented hardware," said Ed Burns, Research Director, Hard Disk Drive and Storage Technologies at IDC. "While not often associated with performance such as low latency, the highest capacity HDDs are a critical strategic asset in the AI development process, filling the need for mass capacity storage of the foundational data essential to building and improving the highest quality AI models in the market today and into the future. Enterprise customers are seeking ways to improve the density of their data centers, lowering power consumption and square footage requirements while ensuring storage continues to meet strategic requirements, and Seagate's new 30TB Exos product is the highest density hard drive offered in the industry today. Hyperscale and enterprise data center customers looking for optimal performance and cost tradeoffs for mass-capacity storage will benefit from Seagate's HAMR product roadmap, which is poised to accelerate areal density growth rates for HDDs in the years to come."
HPE forecasts the on-prem AI market will grow at a 90% CAGR, reaching $42 billion within three years. 1
NVIDIA describes AI factories as 'data centers reimagined to manufacture intelligence at scale,' essential for transforming data into real-time insights across the AI lifecycle. 2
As AI becomes central to business strategy, modernizing storage is not optional—it's foundational.
30TB Hyperscale-Grade Exos & NAS-Optimized IronWolf Pro Arrive Just in Time for On-Prem AI
Edge AI is no longer a future concept—it's happening now. According to IDC, industries such as retail, manufacturing, and financial services are actively deploying AI at the edge for video analytics, predictive maintenance, and fraud detection. This shift is accelerating the adoption of disaggregated storage architectures, which decouple compute from storage to enable more flexible, scalable infrastructure.
The Seagate Exos M 30TB drive is built to meet increased demand for high-capacity, energy-efficient storage—empowering organizations to scale storage, optimize data placement, and support real-time edge analytics without compromising performance or sustainability.
As AI-powered applications proliferate, on-premise NAS systems are evolving into intelligent data hubs—supporting advanced workloads such as video analytics, image recognition, retrieval-augmented generation (RAG), and inferencing at the edge. The convergence of AI, IoT, and hybrid cloud is fueling demand for high-capacity, high-integrity NAS solutions that can manage large, unstructured datasets with low latency and high throughput.
Recent market analysis projects the global NAS market to grow at a CAGR of over 17% through 2034, driven by digital transformation and the rise of AI and big data analytics. 3
'QNAP NAS systems are increasingly used for on-premise AI workloads—enabling enterprises to run local AI models and leverage RAG and LLM technologies to process and analyze local datasets,' said Dhaval Panara, Product Manager, QNAP. 'By integrating Seagate's IronWolf Pro 30TB drives, we deliver petabyte-scale, high-integrity storage that ensures fast access, reliable performance, and scalable infrastructure at the edge.'
'With AI workloads increasingly moving to edge environments, reliable high-capacity storage becomes critical for local data processing. Seagate's IronWolf Pro 30TB drives provide the robust foundation UGREEN NAS systems require—delivering massive scalability and the operational stability needed for local AI applications,' said Evan Li, Head of International Business, UGREEN.
Availability:
The Exos M 30TB & 28TB and IronWolf Pro 30TB & 28TB drives are available now through Seagate online store as well as Seagate's authorized resellers and channel partners worldwide.
Pricing: $599.99 - Exos M & IronWolf Pro 30TB; $569.99 - Exos M & IronWolf Pro 28TB
For more information, please visit Seagate online store:
Exos M:
About Seagate Technology:
www.seagate.com.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
16 minutes ago
- Globe and Mail
UFP Industries to Report Second Quarter 2025 Results on Monday, July 28, 2025
UFP Industries (Nasdaq: UFPI) will announce second quarter 2025 results after the market close on Monday, July 28, 2025. The company will host a conference call to discuss these results on Tuesday, July 29, 2025, at 9 a.m. Eastern Time. A live audio webcast of the call along with supporting materials will be available on the UFP Industries Investor Relations website at and can also be directly by accessing the link here. A webcast replay will be available on the company's website for at least 90 days following the call. UFP Industries, Inc. UFP Industries, Inc. is a holding company whose operating subsidiaries – UFP Packaging, UFP Construction and UFP Retail Solutions – manufacture, distribute and sell a wide variety of value-added products used in residential and commercial construction, packaging and other industrial applications worldwide. Founded in 1955, the company is headquartered in Grand Rapids, Mich., with affiliates in North America, Europe, Asia and Australia. UFP Industries is ranked #128 on Industry Week's list of America's Largest Manufacturers. For more about UFP Industries, go to
Globe and Mail
32 minutes ago
- Globe and Mail
Biosimilars Market worth US$72.29 billion by 2035 with 7.5% CAGR
The biosimilars market is estimated to reach USD 66.9 billion by 2028 from USD 29.4 billion in 2023, at a CAGR of 17.8% during the forecast period. The growth of this market is mainly driven by rising demand for biosimilars in developed and developing countries, favorable reimbursement policies and launch of novel biosimilars in the market. The global Biosimilars Market, valued at US$32.75 billion in 2024 stood at US$35.04 billion in 2025 and is projected to advance at a resilient CAGR of 7.5% from 2025 to 2035, culminating in a forecasted valuation of US$72.29 billion by the end of the period. This growth is driven by several key factors, including a rising number of regulatory approvals and product launches, the patent expiries of major biologics, and the increasing prevalence of chronic diseases that require effective and affordable treatment options. Furthermore, cost containment pressures in global healthcare systems and a surge in R&D collaborations among biopharma companies have significantly accelerated biosimilar development and commercialization. Notably, the first biosimilar version of the blockbuster GLP-1 agonist Semaglutide is projected to launch in China by 2026, and it is anticipated to contribute to approximately 25% of the global biosimilars market share by 2035, underscoring its transformative impact on the market landscape. However, the intricacies involved in the manufacturing processes of biosimilars may present challenges that could impede market expansion throughout the forecast period. Browse in-depth TOC on " Biosimilars Market" 420 - Tables 58 - Figures 391 - Pages By indication, the escalating global burden of cancer, coupled with the high costs associated with biologic therapies, has positioned oncology as the leading segment in the biosimilars market. These biologic medications offer a cost-effective alternative to reference products, thereby improving patient access to crucial treatments. The heightened investment in R&D within oncology has established biosimilars as a strategic option for healthcare systems aiming to enhance treatment affordability. The primary biosimilars utilized for oncological treatments include trastuzumab, bevacizumab, rituximab, filgrastim, epoetin alfa, and denosumab. Ongoing regulatory approvals continue to expand this market segment, while sustained research initiatives and collaborative endeavors are poised to augment market development further. By Drug Class, Infliximab, rituximab, adalimumab, trastuzumab, pembrolizumab, dupilumab, ustekinumab, risankizumab, and other monoclonal antibodies are biologic therapeutics for managing autoimmune diseases, malignancies, chronic conditions, and infectious diseases. These agents are engineered through recombinant DNA (rDNA) technology, enabling them to selectively target specific antigens or cellular receptors, which enhances their therapeutic efficacy and specificity. The introduction of biosimilars for these established mAbs has the potential to significantly reduce healthcare expenditures while improving patient access to vital therapies. Moreover, with the patent expirations of several prominent mAbs, the subsequent surge in market competition is expected to drive down prices and generate increased pharmaceutical interest in mAb development. Given their affordability and versatility across oncology and autoimmune therapy, mAb biosimilars are poised to play a pivotal role in shaping the future landscape of therapeutic options. By geography, the European market has emerged as the leading contributor to the biosimilar sector, driven by pro-biosimilar governmental policies, heightened investments in research and development, and an increasing disease burden. Key suppliers in this arena include France, Italy, Spain, Germany, and the UK. The European Medicines Agency (EMA) has approved 132 biosimilars across various therapeutic classes, enhancing patient access, lowering treatment costs, and expediting market entry. This approval encompasses a range of biologics, including insulin, TNF inhibitors, VEGF inhibitors, and monoclonal antibodies. Notably, in February 2025, the European Commission approved YESINTEK, Biocon Biologics' biosimilar of ustekinumab, underscoring Europe's commitment to improving access to biologic therapies and reinforcing its leadership position in the global biosimilars landscape. Key players in the biosimilars market include Sandoz Group AG (Switzerland), Pfizer Inc. (US), Amgen Inc. (US), Celltrion, Inc. (South Korea), Biocon (India), Dr. Reddy's Laboratories Ltd. (India), Eli Lilly and Company (US), Teva Pharmaceutical Industries Ltd. (Israel), Fresenius Kabi AG (Germany), and STADA Arzneimittel AG (Germany). Biocon (India): In March 2025, Biocon entered into a strategic collaboration with Civica, Inc. to manufacture and market insulin Aspart in the US jointly. As per the agreement, Biocon will provide the drug substance for insulin Aspart, while Civica will handle the downstream processes, including drug development, clinical trials, and the production of the final drug product. This partnership aims to bring biosimilars to the US market, leveraging both companies' strengths in biopharmaceutical development and commercialization. In February 2025, Dr. Reddy's collaborated with Shanghai Henlius Biotech (China) to commercialize HLX15 (daratumumab), a biosimilar candidate to Darzalex and Darzalex Faspro, in the US and Europe. Sandoz Group AG (Switzerland) Sandoz Group AG, a prominent player in the biosimilars sector, has strategically concentrated on launching first-to-market products for high-value biologics, exemplified by its offerings Pyzchiva (ustekinumab) and Tyruko (natalizumab). In addition to its commitment to innovative product launches, Sandoz has enhanced its capabilities in manufacturing, technology, and production capacity. A key development in this arena occurred in May 2023, when Sandoz partnered with Just-Evotec Biologics, a CDMO specializing in continuous biomanufacturing; this collaboration develops and manufactures multiple biosimilars, thereby advancing Sandoz's pipeline to a robust total of 24 assets. For more information, Inquire Now!
Globe and Mail
39 minutes ago
- Globe and Mail
Airgain® Reports Granting of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Airgain, Inc. (NASDAQ: AIRG), a leading provider of advanced wireless connectivity solutions, today announced that it has granted inducement awards to one new employee who recently joined the Company. The awards were made on July 15, 2025, under Airgain's 2021 Employment Inducement Incentive Award Plan, which provides for the granting of equity awards to new employees of Airgain as an inducement to join the company. The inducement awards to the new employee consist of an aggregate of 4,000 restricted stock units ('RSUs'). The RSUs shall vest over four years in substantially equal annual installments on August 15, 2026, 2027, 2028, and 2029, subject to the employee's continued service with the Company through each applicable vesting date. The awards were approved by the Compensation Committee of Airgain's Board of Directors, as required by Nasdaq Rule 5635(c)(4), and were granted as an inducement material to the new employee entering into employment with Airgain in accordance with Nasdaq Rule 5635(c)(4). The awards were not individually negotiated. About Airgain, Inc. Headquartered in San Diego, California, Airgain, Inc. (NASDAQ: AIRG) is a leading provider of advanced wireless connectivity solutions that drive cutting-edge innovation in 5G technology. We are committed to delivering high-performance, cost-effective, and energy-efficient wireless solutions that enable rapid market deployment. Our mission is to connect the world through integrated, innovative, and optimized wireless solutions. Our diverse product portfolio serves three primary markets: enterprise, automotive, and consumer. For more information, visit or follow us on LinkedIn and X.
